Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Mannkind Q3 2026 Results: Net Loss of $23.2M

MannKind Corp reported total revenues of $101.9 million for the third quarter of 2026, a 24% increase year-over-year, driven by commercial product sales and royalties. However, the company swung to a net loss of $23.2 million for the quarter compared to a net income of $8.0 million in the prior year, primarily due to a significant increase in selling, general, and administrative expenses.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue101.982.1
Profit before tax-23.27.8
Net income-23.28.0
EPS (diluted, $ a share)$-0.07$0.03

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+24.0%
Operating margin-2.1%
Source

10-Q filed with the SEC, NASDAQ: MNKD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Mannkind Corp: key numbers

Share price
$3.95Close, Nov 16
Market cap
$1.27B
Shares outstanding
321.64MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Mannkind Corp

All →
4:04 PM ET 8-K
Financial Results

Mannkind Financial Results

MannKind Corporation reported third quarter 2026 total revenues of $101.9 million, a 24% increase year-over-year, driven by the commercial launch of Furoscix ReadyFlow and strong pediatric uptake for Afrezza. The company also highlighted positive Phase 1b results for its nintedanib DPI program and a new licensing collaboration with Rose Pharma for an inhaled GLP-1.

“The third quarter marked an important transition for MannKind as we shifted from delivering on three major catalysts to executing against them. We are focused on scaling two commercial launches while supporting three programs in IPF. Furoscix ReadyFlow is off to an exceptionally strong start, and we believe Furoscix will generate more revenue in the fourth quarter than it did in the first half of 2026. ReadyFlow significantly expands the opportunity ahead and reinforces our conviction that Furoscix can be transformational for MannKind and the patients we serve.”

Michael Castagna, Chief Executive Officer of MannKind

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.